Children's Hospital is part of the UPMC family.
Cancer is the leading non-accidental cause of childhood death. Yet, thanks to research, since the 1970s childhood cancer deaths have declined 35 percent, and in the case of leukemia by 50 percent. However, the battle is not over. Each year 25 percent of children diagnosed with cancer will die of their disease.
Statistics like these fuel a passion to find cures within physicians and scientists of the Division of Hematology/Oncology of Children's Hospital of Pittsburgh of UPMC. The division has extensive research interests in clinical treatment for and basic mechanisms underlying cancer, ultimately aimed at improving clinical therapies. Its commitment to advancing the science of hematology and oncology includes basic research extending into the areas of stem cell biology and molecular oncology.
With so much at stake, Children’s Hematology/Oncology team ranks first in sheer volume of clinical studies within the divisions of Children’s Hospital of Pittsburgh. This is due, in part, to its strong relationship with the Children’s Oncology Group, the only pediatric oncology clinical trials group funded by the National Cancer Institute and National Institutes of Health (NIH). At Children’s, clinical trials are underway related to bone marrow transplantation; treatment of sickle cell disease; cancer control and late-effects in oncology. An ongoing oncology study at Children’s examines incidence of graft-versus-host disease following unrelated donor stem cell transplantation. Children’s is the only institution in the region participating in Phase 1 clinical trials through the Children’s Oncology Group and the Pediatric Brain Tumor Consortium. These important and innovative studies of new cancer treatments are critical to our progress in achieving the goal of curing all children with cancer.
Ongoing NIH-funded oncology projects include the study of critical biochemical events that control the growth, maturation and death of cells that cause leukemia and the study of a family of genes that cause cancers such as Burkitt’s lymphoma and neuroblastoma.
As leaders in their field, Children’s Hematology/Oncology scientists have access to the most advanced tools and resources. Genetic microarray technology, for example, is being utilized in a study on the mechanisms that cause cells to become cancerous or resistant to anti-cancer drugs. This cutting-edge technique, based on results of the Human Genome Project, allows one to measure simultaneously how much protein is being made by more than 5,000 different genes in a single cell at any given time.
The Hematology/Oncology team has not limited itself to the scientific studies of childhood cancers, but also addresses the special medical and psychosocial needs of cancer patients. Through this broad-spectrum approach Children’s Division of Hematology/Oncology continues to forge ahead in its efforts to explore, diagnose, treat and cure childhood cancers.
Physicians at Children’s Hospital are also active in clinical care and research in diseases of blood other than cancer. Sickle cell disease is a serious chronic illness of the red blood cell that is complicated by anemia, stroke, lung complications and decreased quantity and quality of life. The sickle cell program at Children’s Hospital is one of eight sites around the world that are participating in a clinical trial to determine the prevalence of pulmonary hypertension a serious complication involving the heart and lung. Patients found to have pulmonary hypertension will be treated in a randomized double-blind study of a drug called sildenafil. This groundbreaking study is expected to provide information on a serious and little understood complication of this disease.
Risk-Adapted Chemotherapy in Treating Younger Patients with Newly Diagnosed Standard-Risk B-Acute Lymphoblastic Leukemia or localized B-Lineage Lymphoblastic Lymphoma
Proper Protocols for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens
Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Trial for Patients with de novo Acute Myeloid Leukemia using Bortezomib and Sorafenib for Patients with High Allelic Ratio FLT3/ITD
Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia using Arsenic Trioxide and All Trans-Retinoic Acid
Brentuximab Vedotin or Crizotinib in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma
Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor
Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors
A Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors
Study of Peginterferon alfa-2b (PEGIntron) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma
MK-1775 and Local Radiation Therapy in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas
Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma
Treatment for Recurrent Ependymomas in Children Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod
A Children’s Oncology Group Protocol for Collecting and Banking Ewing Sarcoma Specimens
Adding the IGF-1R Monoclonal Antibody Ganitumab to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma
Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma
Vaccinations with HLA-A2-Restricted Glioma Antigen-Peptides in Combination with Poly-ICLC for Children with Recurrent Unresectable Low-Grade Gliomas (LGG)
Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma
ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas
Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Gliomas
Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia, Testing Clofarabine in the Very High Risk Stratum
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients
Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
Brentuximab Vedotin in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma
Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial
Study of Eribulin Mesylate, a Novel Microtubule Targeting Chemotherapeutic Agent, in Children with Refractory or Recurrent Solid Tumors including Lymphomas
Study for the Treatment of Non-Metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age
Intergroup Trial for Children or Adolescents with B-cell Non-Hodgkin Lymphoma or Mature B-cell Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients
Human-Mouse Chimeric Anti-Disialoganglioside Monoclonal Antibody ch14.18 (Dinutuximab) in Combination with GM-CSF (Sargramostim) in Patients with Recurrent Osteosarcoma
A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens
A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors
Trial of Lenalidomide in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas
Peginterferon alfa-2b in Treating Young Patients with Unresectable, Sympotomatic or Life-Threatening Plexiform Neurofibromas Associated with Neurofibromatosis Type 1
A Study of Hematopoietic Stem Cell Therapy for Young Adults with Severe Sickle Cell Disease
Patient-Centered Comprehensive Medication Adherence Management System to Improve Effectiveness of Disease Modifying Therapy with Hydroxyurea in Patients with Sickle Cell Disease
Pazopanib Neoadjuvunt Trial on Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib
PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma
Crizotinib in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma
MK-1775 in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors
A Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
Bortezomib on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Biology Study of Transient Myeloproliferative Disorder in Children with Down Syndrome
BMN 673, an Oral Poly Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies
Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor
Children's Hospital's main campus is located in the Lawrenceville neighborhood. Our main hospital address is:
Children’s Hospital of Pittsburgh of UPMC
One Children’s Hospital Way
4401 Penn Ave.
Pittsburgh, PA 15224
In addition to the main hospital, Children's has many convenient locations in other neighborhoods throughout the greater Pittsburgh region.
With myCHP, you can request appointments, review test results, and more.
For questions about a hospital bill call:
To pay your bill online, please visit UPMC's online bill payment system.
Interested in giving to Children's Hospital? Visit Children's Hospital of Pittsburgh Foundation's website to: